Oligodendrocyte Dysfunction and Global CNS Dysmyelination Occur in Arginase Deficiency that is Prevented with AAV-based Hepatic Gene Therapy



Jenna Lambert¹, Xiao-Bo Liu¹, Suhail Khoja¹, Matt Nitzahn¹, Adam Eliav¹, Steve Cederbaum^{1,2}, Gerald S. Lipshutz^{1,2}

Department of Surgery¹ and Intellectual and Developmental Disabilities Research Center at UCLA², UCLA School of Medicine



Lipshutzlabucla.com

BACKGROUND

Arginase (Arg1):

- Arg1 functions predominantly in the liver as a catalyst in the urea
- cycle; Arginase deficiency (AD) results from a loss of hepatic Arg1.
- o AD-associated neuromotor manifestations have recently been
 - attributed to dysmyelination in the corticospinal tract (CST).

□ To understand the effects and mechanism of Arginase 1 deficiency on the

developing nervous system and how it relates to dysmyelination.

□ To visualize and quantify the difference in expression of myelination and

related proteins in the developing murine brains between wild type, Arginase 1

deficient, and AAV-treated Arginase 1 deficient mice.

DISCUSSION

CLARITY:

• Preliminary imaging of cleared P12 Arg1/PLP-eGFP brains shows

decrease signal in Arg1-KO mice, most notably in regions of the CST.

Signal is restored in P12 TKO brains.

• Observed decrease in PLP-eGFP signal appears more reduced in

Preliminary Data:

- o Microarray data indicate a down-regulation of myelination and oligodendrocyte (OL) related genes in Arg1 knockout (Arg1-KO) mice (Liu et al., 2019).
- Our previous work in brain pathology for Arg1-KO mice shows decreased myelin density in subcortical white matter of the motor cortex and pyramidal tract (Liu et al., 2019).
- seek to further understand the dysmyelination in the o We developing Arg1-KO CNS, explore potential mechanisms of its
- cause, and evaluate the efficacy of our gene therapy for its

prevention.









the Arg1-KO in regions originating in the cerebral cortex than in the structures of the mid brain. This could be in part due to the directionality of myelination development from brain stem to cortex. • Greater signal intensity observed in TKO than WT speculated to be from repair or overcompensation of myelination due to delay between P2 AAV treatment and onset of oligodendrogenesis (prenatal).

Electron Microscopy:

 Arg1-KO mice show reduced myelination in the CST with almost no myelination in the subcortical white matter and little in the pyramidal tract by P14; when found, OLs appear to be inactive Quantitatively, the subcortical white matter and pyramidal tract are

severely dysmyelinated during development.

o In TKO mice, WT-level myelination density is maintained in CST in

Visualization of CNS Myelination Levels:

- Post-natal day (P)12 Arg1/PLP-eGFP whole mouse brains were
- cleared by active CLARITY low current electrophoretic tissue
- clearing. Myelin proteolipid protein 1 (PLP) was used as a marker of myelination.
- Image acquisition performed by light sheet microscopy and 3D rendering done by IMaris.

Electron Microscopy:

 Myelination was quantified in subcortical white matter and pyramidal tract of Arg1-KO, WT, and Arg1-KO AAV-treated (TKO) mice at time points P2, P6, P10, and P14 by electron microscopy.

WT and TKO mice were also examined at 4 months.

Figure 1: Imaris 3D rendered Arg1/PLP-eGFP CLARITY-cleared brains imaged with light sheet microscopy. Brains were imaged at 4x magnification in the transverse plane of (A) Arg1-KO (B) TKO and (C) WT P12 mice. Red box outlines the frontal lobe of the cortex. Arrows indicate regions of interest within CST. Blue arrow points to the corpus callosum (part of white matter motor cortex), pink arrow points to the caudoputamen (part of striatum); yellow arrow points to the fimbria (white matter leading to hippocampal commissure; part of striatum). Scale bar represents 100µm.

Δ	7	R	X	
	Z	B		

the long-term (4 months).

Protein Expression:

• Western blot analysis of P12 mice suggests decrease in MBP, NeuH, and Olig2 expression in the frontal cortex of A1-KO mice. TKO mice show NeuH and Olig2 expression at levels comparable to WT. • Olig2 and MBP reduction in Arg1-KO mice suggests a potential dysmyelination mechanism by impairment of OL development. Reduction of NeuH suggests axonal damage due to lack of myelination. Early postnatal gene therapy appears to restore OL function and prevent axonal damage.

ACKNOWLEDGEMENTS

• EM work performed by Xiao-Bo Liu

• Access to CLARITY equipment courtesy of Geschwind Lab



• Expression of myelin-basic protein (MBP), oligodendrocyte

transcription factor 2 (Olig2), and neurofilament heavy chain

protein (NeuH) were examined by western blot analysis on frontal

cortex of Arg1-KO, WT, and TKO mice at P12.



Figure 2: Orientation of brains for light sheet microscopy imaging. (A) Defines the orientation of the X-Y-Z axes used. (B) Shows position of brains in the transverse plane used to acquisition all images.

• Funding to GSL by NIH grants RO3NS101682 and RO1NS110596



• Richardson, D.S. (2015). Clarifying tissue clearing. *Cell*, 162(2). o © 2004 Allen Institute for Brain Science. Allen Mouse Brain Atlas. Available from: mouse.brainmap.org/static/atlas o Liu, X. B., Haney, J. R., Cantero, G., Lambert, J. R., Otero-Garcia, M., Truong, B., ... & Lipshutz, G. S. (2019).

Hepatic arginase deficiency fosters dysmyelination during postnatal CNS development. JCI insight, 4(17).